BrickBio expands antibody-drug conjugate programs

By The Science Advisory Board staff writers

BrickBio said it has received positive data on its first clinical novel antibody-drug conjugate candidate for treating breast cancer and gastric cancer.

In data reported by a contract research organization, BrickBio's BRKB-28 preclinical antibody was found during in vitro testing to eradicate the cancerous targets without targeting or adversely affecting healthy cells, according to the company.

BrickBio also said that it has expanded its internal programs aimed at developing biologics using the company's unnatural amino acid incorporation technology platform. The technology platform, which produces site-selective and site-specific unnatural amino acid coupled protein conjugation, allows the company to precisely control the drug to antibody ratio (DAR) within a homogenous product. These programs include antibody drug conjugates, novel bispecific antibody conjugates, and novel scaffolds.

Copyright © 2020

To read this and get access to all of the exclusive content on The Science Advisory Board create a free account or sign-in now.

Member Sign In:
MemberID or email address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?